Market: NMS |
Currency: USD
Address: 203 Redwood Shores Parkway
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
📈 Soleno Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$105.15
-
Upside/Downside from Analyst Target:
148.24%
-
Broker Call:
25
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-05-07
-
EPS Estimate:
0.50
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Soleno Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-06 (estimated upcoming) | - |
| 2026-02-25 | 0.8 |
| 2025-11-04 | 0.47 |
| 2025-08-06 | -0.09 |
| 2025-05-07 | -0.95 |
| 2025-02-27 | -1.27 |
| 2024-11-06 | -1.83 |
| 2024-08-07 | -0.57 |
| 2024-05-09 | -0.59 |
| 2024-03-06 | -0.33 |
| 2023-11-07 | -0.95 |
| 2023-08-08 | -0.81 |
| 2023-05-09 | -0.88 |
| 2023-03-21 | -0.58 |
| 2022-11-09 | -0.76 |
| 2022-08-10 | -0.9 |
| 2022-05-10 | -1.05 |
| 2022-03-31 | -0.6 |
| 2021-11-10 | -1.5 |
| 2021-07-28 | -2.1 |
| 2021-05-05 | -1.65 |
| 2021-03-03 | -0.6 |
| 2020-11-10 | -1.65 |
| 2020-08-10 | -2.4 |
| 2020-05-12 | -2.92 |
📰 Related News & Research
🔍 View more Reports
